Halozyme Therapeutics, Inc. (HALO) — 10-Q Filings

10-Q Filings (6)

• Halozyme's Royalties Fuel 49% Net Income Surge in Q3 — Nov 3, 2025 Risk: medium
  HALOZYME THERAPEUTICS, INC. reported a robust financial performance for the nine months ended September 30, 2025, with total revenues increasing by 31.7% to $94
• 10-Q Filing — Aug 5, 2025
• Halozyme Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: low
  Halozyme Therapeutics, Inc. filed its Q1 2025 10-Q report on May 6, 2025, detailing financial performance for the period ending March 31, 2025. The company, bas
• Halozyme Therapeutics Files Q3 2024 Report — Oct 31, 2024 Risk: low
  Halozyme Therapeutics, Inc. filed its quarterly report for the period ended September 30, 2024. The company, incorporated in Delaware, is headquartered in San D
• Halozyme Therapeutics Q2 Revenue Declines — Aug 6, 2024 Risk: medium
  Halozyme Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported royalty revenues of $142.4 million for the second quarter o
• Halozyme Therapeutics Reports Q1 2024 Results — May 7, 2024 Risk: low
  HALOZYME THERAPEUTICS, INC. (HALO) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Revenue for the first quarter of 2024 was $177.6 million, a 12%

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX